Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. BBIO
10. RCKT

Go back to Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015

August 5, 2015 4:15 PM EDT

SAN FRANCISCO, Aug. 5, 2015 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2015.

Cash and investments in marketable securities at June 30, 2015 were $279.7 million as compared to $325.8 million at March 31, 2015.  

"We are pleased that the MOVANTIK launch in the U.S. is off to an encouraging start with very rapid uptake," said Howard W. Robin, President and Chief Executive Officer of Nektar. "AstraZeneca plans to launch MOVANTIK in both Europe and Canada in the second half of this year. The... More